DOI: 10.36347/sjams.2018.v06i01.074

Pages: 366-370

Multiple myeloma is a hematological malignancy characterized by the monoclonal proliferation of neoplastic plasma and cytogenetic studies have shown numerous chromosomal abnormalities that play crucial roles in disease progression in myeloma patients. Studies have shown cyclin D1 expression to be associated with advanced clinical stage, and poor prognosis. The study aims to assess the cyclin D1 expression in newly diagnosed multiple myeloma using immunohistochemistry, and correlating it with the clinical parameters. A total of 50 newly diagnosed cases of multiple myeloma were included in the study. Cyclin D1 expression was assessed by immunohistochemistry, with mantle cell lymphoma taken as positive control. Expression of cyclin D1 was correlated with clinical parameters. SPSS statistical software was used for all statistical analysis. Majority of the patients were male (60%), with median age of 59.96 years at diagnosis. Seventy two percent of patients had anemia and 90% had bone involvement at presentation. Sixty percent of the patients presented with ISS stage 3. The predominant pattern of marrow infiltration by plasma cells was found to be diffuse (64%), followed by an interstitial pattern. Twenty eight patients (56%) showed cyclin D1 over expression with 14(28%) showing strong expression (2+/3+). A significant association between the cyclin D1 expression and a higher histological grade was found (p value= 0.05). Expression of cyclin D1 could not be correlated with a higher ISS stage in the present study. Cyclin D1 positivity is found in 56% of patients with newly diagnosed myeloma and its expression correlated with a higher histological grade.